ClinicalTrials.gg
Not yet recruitingNCT07939607IDeASUpdated Nov 16, 2026

IDeAS Probiotic Pilot

An observational study in Staphylococcus Aureus Colonization, sponsored by Washington University School of Medicine. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Washington University School of Medicine · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

Infections caused by Staphylococcus aureus pose a major public health threat, and existing prevention methods are burdensome to patients and provide only limited benefit. In this collaborative study, participants will trial a probiotic intervention and share their perspectives regarding study design and feasibility. The goal of this study is to characterize colonization kinetics of S. aureus and B. subtilis in the nares, skin, and stool before, during, and after administration of a nutritional supplement probiotic blend. We will establish the S. aureus intestinal colonization kinetics over a 3-month Natural History Phase, followed by a 1-month administration of the probiotic (Intervention Phase), and a 3-month Post-Intervention Observational Phase. Samples from the nares, skin, and stool will be collected at each of the 10 study visits to detect S. aureus and B. subtilis. We will also conduct interviews to assess acceptability, appropriateness, and feasibility of the probiotic and study regimen.

Read the detailed description

The ongoing epidemic of Staphylococcus aureus skin and soft tissue infections in healthy individuals is a significant public health burden. S. aureus colonization (having the germ living in or on the body without symptoms) poses risk for developing symptomatic S. aureus infections. Thus, topical antimicrobials and antiseptics are often used to eliminate or reduce the burden of S. aureus from the nose and skin (known as decolonization). While current decolonization practices with topical antimicrobials effectively eliminate S. aureus carriage and prevent recurrent infections in the immediate period, their effectiveness wanes over time. While the nose has traditionally been considered the primary reservoir of S. aureus carriage, the intestine is also an important, yet under-appreciated, reservoir of S. aureus. Intestinal colonization can lead to persistent S. aureus colonization at other body sites despite topical antimicrobial decolonization.

Probiotics can promote a healthy gut microbiome by increasing the presence of beneficial bacteria and reducing the presence of pathogens, thereby improving digestive health and enhancing immune function. Bacillus subtilis is a benign microorganism that has been shown to inhibit S. aureus from colonizing the intestine. In a trial conducted in rural Thailand, daily oral administration of B. subtilis MB40 significantly reduced S. aureus in stool and nasal samples, without adverse effects. Bacillus coagulans has been demonstrated to decrease gastrointestinal symptoms, without adverse effects. B. subtilis and B. coagulans are both included as supplements in foods and available in pill form. In this investigation, we will study a probiotic blend of B. subtilis and B. coagulans, which is commercially available as a nutritional supplement, Ameo LifeTM Digest Probiotic. The goals of this study are to 1) establish the longitudinal colonization kinetics of S. aureus and B. subtilis before, during, and after probiotic administration; 2) assess the tolerability and delivery fidelity of the probiotic administration; and 3) engage participant perspectives to optimize study procedures and develop an intervention that is acceptable, appropriate, feasible, and likely to be adopted in real-world settings.

In this study, 20 healthy adults who are at risk for S. aureus infection who are colonized with S. aureus will be enrolled. S. aureus-colonized participants will be followed during a 3-month Natural History Phase, followed by a 1-month administration of the probiotic, and finally, a 3-month Post-Intervention Observational Phase. Stool, nasal, and skin samples will be collected 10 times over 7 months to quantify S. aureus and B. subtilis longitudinally. Participant acceptability and appropriateness will be assessed through brief, semi-structured interviews at the end of the probiotic administration and the conclusion of the Post-Intervention Observational Phase.

02

Conditions studied

  • Staphylococcus Aureus Colonization

Keywords

  • Probiotic
  • Staphylococcus aureus
  • Bacillus subtilis
  • Staphylococcus aureus colonized
03

In context

Staphylococcal Infections

304 studies on the registry are indexed under Staphylococcal Infections; 35 are open to participants now.

This study's planned enrollment of 20 is below the median of 190 across 91 observational studies indexed under Staphylococcal Infections.

Browse Staphylococcal Infections studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.

Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants meeting eligibility criteria who provide written informed consent. Participants will be recruited from a pre-existing participant pool developed through prior studies conducted by our research team. Participants will be from St. Louis, Missouri and surrounding areas.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Colonized with S. aureus in anterior nares, inguinal folds, or stool
  2. Age ≥ 18 years
  3. Able to complete the process
  4. Willing and able to complete the study protocol, study-related activities, and visits

Exclusion criteria

Exclusion Criteria

  1. Pregnant or planning to become pregnant in the next 9 months
  2. Breastfeeding
  3. Abnormalities of the gastrointestinal tract (e.g., inflammatory bowel disease, ulcers, celiac diseases, etc.)
  4. Immunodeficiency
  5. Use of any antibiotics or probiotics outside of the study within 90 days of study screening
  6. Any to taking probiotics
  7. No permanent home, or living in a group home/ long term care facility
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Target follow-up
9 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • Dietary supplementAmeo LifeTM Digest Probiotic, a dietary supplement comprised of a proprietary blend of two Bacillus species that have been widely studied: B. subtilis ATCC 122264 and B. coagulans MTCC 5856

    Participants will take Ameo Life Digest Probiotic once each day for 30 days. All participants will receive the intervention; there will be no randomization or placebo.

06

What researchers measure

Primary outcomes

  1. Characterize S. aureus in the stool from the pre-intervention sampling to the Week 4 sampling (completion of the Intervention Phase)

    Compare change in S. aureus log10 S. aureus CFU/g count in stool from the pre-intervention sampling to the week-4 (end-of-dosing) sampling.

    Time frame: Start of the pre-intervention phase and end of the intervention phase

  2. Evaluate the implementation outcomes of acceptability, appropriateness, and feasibility of the study procedures from the participant's perspective.

    Create a participant-informed account of what makes the regimen acceptable and appropriate, benchmarked feasibility data against pre-specified go/no-go thresholds, and a prioritized set of protocol refinements. Comparing facilitators and barriers at the end-of-intervention visit versus the end-of-follow-up visit will indicate whether acceptability changes over time, and benchmarks falling below the thresholds will pinpoint where recruitment, retention, or scheduling procedures require modification.

    Time frame: End of the intervention phase and end of the post-intervention phase

Secondary outcomes

  1. S. aureus nares pre-intervention to week-4 (end-of-dosing) sampling.

    Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-4 (end-of-dosing) sampling.

    Time frame: Pre-intervention to week-4 sampling

  2. S. aureus nares pre-intervention to week-6 sampling.

    Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-6 sampling.

    Time frame: Pre-intervention to week-6 sampling

  3. S. aureus nares pre-intervention to month 2 sampling.

    Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 2 sampling.

    Time frame: Pre-intervention sampling to month 2 sampling.

  4. S. aureus nares pre-intervention to month 3 sampling.

    Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 3 sampling.

    Time frame: Pre-intervention sampling to month 3 sampling.

  5. S. aureus nares pre-intervention to month 4 sampling.

    Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 4 sampling.

    Time frame: Pre-intervention to month 4 sampling.

  6. S. aureus inguinal fold pre-intervention to week-4 (end-of-dosing) sampling.

    Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-4 (end-of-dosing) sampling.

    Time frame: Pre-intervention to week-4 sampling

  7. S. aureus inguinal fold pre-intervention to week-6 sampling.

    Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-6 sampling.

    Time frame: Pre-intervention to week-6 sampling

  8. S. aureus inguinal fold pre-intervention to month 2 sampling.

    Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 2 sampling.

    Time frame: Pre-intervention sampling to month 2 sampling.

  9. S. aureus inguinal fold pre-intervention to month 3 sampling.

    Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 3 sampling.

    Time frame: Pre-intervention sampling to month 3 sampling.

  10. S. aureus inguinal fold pre-intervention to month 4 sampling.

    Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 4 sampling.

    Time frame: Pre-intervention sampling to month 4 sampling.

  11. Bacillus stool pre-intervention

    log10 B. subtilis CFU count at pre-intervention sampling

    Time frame: Pre-intervention sampling

  12. Bacillus stool week-2 sampling

    log10 B. subtilis CFU count at week-2 sampling

    Time frame: Week-2 sampling

  13. Bacillus stool week-4 sampling

    log10 B. subtilis CFU count at week-4 sampling

    Time frame: Week-4 sampling

  14. Bacillus stool week-6 sampling

    log10 B. subtilis CFU count at week-6 sampling

    Time frame: Week-6 sampling

  15. Bacillus stool month 2 sampling

    log10 B. subtilis CFU count at month 2 sampling

    Time frame: Month 2 sampling

  16. Bacillus stool month 3 sampling

    log10 B. subtilis CFU count at month 3 sampling

    Time frame: Month 3 sampling

  17. Bacillus stool month 4 sampling

    log10 B. subtilis CFU count at month 4 sampling

    Time frame: Month 4 sampling

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Piewngam P, Zheng Y, Nguyen TH, Dickey SW, Joo HS, Villaruz AE, Glose KA, Fisher EL, Hunt RL, Li B, Chiou J, Pharkjaksu S, Khongthong S, Cheung GYC, Kiratisin P, Otto M. Pathogen elimination by probiotic Bacillus via signalling interference. Nature. 2018 Oct;562(7728):532-537. doi: 10.1038/s41586-018-0616-y. Epub 2018 Oct 10. PubMed 30305736 ↗
  • Piewngam P, Khongthong S, Roekngam N, Theapparat Y, Sunpaweravong S, Faroongsarng D, Otto M. Probiotic for pathogen-specific Staphylococcus aureus decolonisation in Thailand: a phase 2, double-blind, randomised, placebo-controlled trial. Lancet Microbe. 2023 Feb;4(2):e75-e83. doi: 10.1016/S2666-5247(22)00322-6. Epub 2023 Jan 13. PubMed 36646104 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2030, 48 months later.

Of 22 observational studies under Staphylococcal Infections, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2030
CompletionEst.
Nov 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939607
Responsible party
Stephanie A. Fritz (The Ferring Family Chair Professor of Pediatrics, Washington University School of Medicine) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2030 (estimated)
Completion
Nov 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Stephanie Fritz, MD, MSCI
Contact
Fritz.s@wustl.edu
(314) 454-4114
Mary Boyle, RN, MSN
Contact
mboyle@wustl.edu
3(14) 286-1207
Stephanie A Fritz, MD, MSCI
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion